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Background: TPN infusions are usually administered during a treatment period of 10–24 hours per day due to
the metabolic capacity of the liver. During this time interval physicochemically stable TPN solution (emulsion) is
needed for the treatment. The purpose of the present study was to examine how the kinetic stability features
of ready-made total parenteral nutrition admixtures containing olive oil and soybean oil will change under the
usage-modeling 24-hour application with and without overdose Ca2+.
Methods: Particle size analysis and zeta potential measurements were carried out to evaluate the possible changes
in the kinetic stability of the emulsions.
Results: Our results indicate that in two of the four mixtures bimodal droplet-size distribution figures were detected
and appearance of fat particles over 5 μm can not be disclosed. The tendency for separation of large diameter
droplets in the two types of oil-based emulsion systems was different. In case of soybean containing emulsion
second peak of droplets appeared in the bottom of the container in contrast to the olive oil containing emulsions
where the second peak appeared in the surface layer. Interestingly this phenomenon is independent
of calcium-content.
Conclusions: From therapeutic point the emulsions of the bigger droplets containing upper layer are safer because
the potentially dangerous big droplets could remain in the infusion bag after the administration.
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Total parenteral nutrition admixtures
Since over two decades it is well-known that good avail-
ability of nutrients can be reached by simultaneous admin-
istration of macronutrients. Clinical nutrition therefore is
made by use of nutrient admixtures. Should we concen-
trate to the intravenous nutrition, these solutions are basi-
cally composed of amino acids, glucose and fat emulsions
therefore they are called as all-in-one mixtures. Usually,
additional important ingredients like electrolytes, trace ele-
ments and vitamins, are also concomitantly admixed and
the final product is named as total parenteral nutrient
(TPN) mixture [1]. There are special conditions (e.g. high* Correspondence: zelrom@gytk.sote.hu
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reproduction in any medium, provided the orrisk of tetanic contraction or electrolyte depletion in case
of cardiac surgery with extracorporeal circulation) when
extra electrolytes are needed. Typically Ca2+ and phos-
phate are the boosted ions out of which Ca2+ is more
dangerous in oil-containing mixtures due to the bivalent
cation property that can damage lipid-droplet surface
charge and so the repulsive force. TPN infusions are usually
administered during a treatment period of 10–24 hours per
day due to the metabolic capacity of the liver.
During this time interval physicochemically stable TPN
solution (emulsion) is needed for the treatment. In our
previous studies the droplet size stability of all-in-one nu-
tritive mixtures containing different fat emulsions were
studied. Authors concluded that droplet stability of
MCT/LCT lipids surpassed the pure LCT [2] and the
SMOF-lipid was more stable than that of MCT/LCT [3].
In our present study we broadened the range of lipidsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of mainly MUFA that has a lot of beneficial properties,
primarily the stability against lipid-peroxidation [4]. This
is important in case of storage because in the plastic
(EVA) bags used for storage of TPNs peroxidation of
lipids is much more pronounced than that in glass bot-
tles [5]. In human studies, however the protective action
against oxidative stress is controversial [6,7]. Aging
process in oil-containing colloid systems may increase
critical flocculation concentration of eg. Ca2+ in the emul-
sions [8] and the lipid-peroxidation can play a role in the
aging processes of colloid systems like oil-containing
TPNs, this property of olive oil can be of importance in
case of kinetic/physical stability of all-in-one nutrient mix-
tures however, we did not study the details of aging
process itself in this experiment.
The aim of the present study was to demonstrate any
clinically significant physicochemical difference between
two TPNs containing LCT-based lipid emulsion regard-
ing the droplet-size and zeta potential.
Physicochemical considerations
Total parenteral nutrition admixtures are colloid disper-
sion systems, where droplet-size should be under 5 μm in
long-term. This size limit remains under the human red
blood cell diameter (6–8 μm) and so producers and users
can avoid occlusion of capillaries due to the fat-droplets
in the infusion. Stable lipid-emulsions used in the iv ther-
apy are usually monodisperse systems with a mean droplet
diameter of 200–600 nm, and according to the Gauss-
distribution with lower and upper limits of 95% at ca.
50 and 1000 nm respectively. According to the USP drop-
lets with diameter higher than 5 μm are still allowed in par-
enteral lipid emulsions and in therapeutic admixtures but
they must not exceed the proportion of 0.05% [9]. In emul-
sions used as human pharmaceuticals the droplets are usu-
ally stabilized with any type of lecithin. The Stern-layer
around the small fat globules in the water-based emulsions
like all-in-one iv nutritions, is a stable interface where the
surrounding ions are strongly bound to the globules. The
stability of this system depends on the repulsive and at-
tractive colloidal forces, such as van der Waals, electrical
double-layer and steric forces that act between the dro-
plets. The repulsive force on the surface of the fat droplet
can be measured as zeta-potential. In case of this type of
emulsions negative charge of oil droplets below −30 mV
means that the system is stable enough to be used for
intravenous nourishment of patients [10]. Should we
affect the density of the Stern-layer around the droplets
by altering the conductivity (eg. addition of bivalent
cations) we jeopardize the stability of the whole system,
therefore monitoring of zeta-potential and the droplet-size
in a new composition is essential before using it for treat-
ment of patients.Methods
Materials
Industrial convenience systems of OliClinomel N6-900 E
(Baxter) and Kabiven (FreseniusKabi) were used as all-
in-one nutrient mixtures. OliClinomel contains 80% of
olive oil (LCT, in 60-80% esterified by C18-MUFA of
the ω-9 subgroup) and 20% of soybean oil (LCT, mainly
triglyceride esters composed of C-18:2 PUFA of the ω-6
subgroup). Kabiven contains 100% soybean oil (LCT, mainly
C18:2 PUFA esters). The three-chamber bags were reconsti-
tuted according to the instruction for use by breaking the
non-permanent seals between the compartments and then
mixing them by inverting the bag [10].
An overdose of Ca-gluconate (25 ml into 1000 ml out
of 100 mg/ml injection = 5.5 mmol/l Ca2+ extra) was
added during the preparation process to one of the TPN.
Ingredients in g/l and mmol/l after reconstitution and
additional Ca-gluconate are as follows:
OliClinomel (samples OA and OC)
Macronutrients: 34 g/l Amino acids, 120 g/l Glucose,
40 g/l Fat
Micronutrient: 32 mmol/l Na+, 24 mmol/l K+,
2.2 mmol/l Mg2+, 2 mmol/l (Sample OA) and
7.5 mmol/l (Sample OC) Ca2+, 10 mmol/l
Phosphate, 53 mmol/l Acetate and 46 mmol/l Cl-.
Kabiven (samples KA and KC)
Macronutrients: 33 g/l Amino acids, 100 g/l Glucose,
39 g/l Fat
Micronutrients: 31 mmol/l Na+, 23 mmol/l K+,
3.9 mmol/l Mg2+, 1.9 mmol/l (Sample KA) and
7.4 mmol/l (Sample KC) Ca2+, 9.7 mmol/l
Phosphate, 3.9 mmol/l Sulphate, 38 mmol/l
Acetate and 45 mmol/l Cl-.
Previously it was found that a moderate difference (up
to 20%) in glucose content did not influence the droplet-
stability under very similar electrolyte-environment [3].
So we can state that the two TPN systems studied in
our present experiments are comparable. Test mixtures
signed with C contain ca. 50% more Ca2+ than maximally
advised by the manufacturers and it was considered the
possible upper limit of Ca2+ content in the comparison of
the stability of different mixtures.
Sampling
After shaking the solution container, it has been connected
to an infusion set and hanged up to an infusion stander.
Light protection was not used and the storage temperature
was hospital ward room-temperature (22–24°C). After a lag
time of 5 minutes infusion administration with a speed of
2 ml/min (= 120 ml/hours) has been started. Samples for
droplet-size control measurements were taken from the
“supernatant” of the infusion bag content (within 3 mm of
Figure 1 Mode droplet size values of different fractions of
admixtures at the initial (without up or low index) point and
after 24 hours.
Table 1 Appearance of second peak in droplet size and
their ratios
Droplet size and intensity ratio
Sample 1st peak (nm) Intensity ratio 2nd peak (nm) Intensity ratio
KA-up 158 100 0 0
KA-low 185 97.5 2545 2.5
KC-up 231 100 0 0
KC-low 174 93.3 2290 6.7
OA-up 171 95.2 2115 4.8
OA-low 1401 100 0 0
OC-up 154 96 2343 4
OC-low 135 100 0 0
Télessy et al. Nutrition Journal 2012, 11:32 Page 3 of 5
http://www.nutritionj.com/content/11/1/32the surface, later mentioned as “upper level sample” signed
as “up”) and from the infusion tube 25 cm after the out-
put port of the container bag (“lower level sample” in
short “low”). Samples (5 ml) have been taken just after the
start (zero point) and 24 hours later (end point). For zeta-
potential measurements we took samples from the middle
of the container and sampling was done at start, after 1, 2,
3, 10, 11, 12 hours to simulate the real parenteral nutrition
conditions and in the end of the study period (24. hour).
Laboratory measurements
Droplet size measurements were performed by photon-
correlation spectroscopy (PCS, made by Zetasizer 4 and
Nanosizer ZS, Malvern Instruments, England) and the
surface-charge was checked by measurement of electro-
phoretic movement (Laser Doppler Anemometry by
Zetasizer 4, Malvern Instruments, England). Droplet size
distributions and zeta-potential figures were made out
of 2 or 3 separate samples in each measurement depend-
ing on the coherence of measurement results. Nature
samples were diluted by purified water in a proportion of
1:300 in order to reach the measurement concentration-
range according to the manual for use of the equipment.
The measurement limits of the Zetasizer 4 equipment
are 3-3000 nm for determination of droplet size and
20-20000 nm in case of LDA [11]. The measuring range
of the Zetasizer Nano ZS equipment (Dynamic Light
Scattering principle) for particle size measurement
is between 0.3 nm-10 μm and for zeta-potential
3.8-100000 nm [12]. We expected the 99.5% of dro-
plets in the range of 10-3000 nm with the main peak
between 300-700 nm and the critical point was the
size over 5 μm. Surface charge of droplets was
expected between −40 and −10 mV. Droplet-size con-
trol was performed according to the accepted rules based
on the USP [13,14]. We also controlled the droplet stabil-
ity by electrokinetic (zeta-potential) measurement as
advised [15].
Results and discussion
In our study we simulated the two endpoints of a typical
clinical situation of nutrition therapy. Therefore the
duration of inspection was just 24 hours. Under clinical
conditions one dose of TPN (usually 1–3 litres for adults) is
not administered in a shorter period than 8 hours and not
longer than 24 hours. After preparation of the iv solutions
we immediately checked the main parameters according to
the above mentioned schedule. The comparison of the
mode droplet-size values shows that different nutrient test-
solutions with and without additional Ca2+ are within the
expected droplet size range of 0.2-0.6 μm. The MDS
situation of different test mixtures at beginning and at the
end of the 24 hour of infusion did not change significantly
(Figure 1). The large-size tail of the distribution-figure wasanalyzed at the end of the study in both sites of surface layer
and after the port. At 24 hours we realized that in the
supernatant phase and in the infusion line small proportion
of droplets over 5 μm could be detected. Intensity-weighted
distributions (Table 1) demonstrate that only in infusion
line samples of Kabimix and in the supernatant phase of
OliClinomel appeared a second peak of 2552-2883 nm
(KA) and 1851-3006 nm (KC) as well as 2277-2816 nm
(OA) and 2265-2895 nm (OC) respectively. Exact propor-
tion of over 5 μm droplets could not be estimated in this
study.
Electrokinetic properties of emulsion were demonstrated
by measurement of zeta-potential. Test-results explain that
mean charge of droplet surface in all samples remained
under −30 mV (Table 2). It means that the electrokinetic
parameter supports droplet size stability features measured
with globule-size distribution techniques.
The ageing of emulsions usually brings increase in
droplet-size. In clinical use droplet size stability should be
reserved during the time of infusion, in case of intravenous
nutrition within 24 hours as well. Our results demonstrate
that vast majority of droplet remained within the safe range
Table 2 Mean surface charge (mV) of droplets in different
TPN mixtures in course of the nutrition period
Sample Nutrition period (h)
0 1 2 3 10 11 12 24
Mean surface charge (mV)
KA −39.10 −37.80 −38.30 −38.00 −38.10 −37.60 −36.20 −36.20
KC −34.00 −33.50 −34.60 −33.50 −33.40 −32.60 −38.30 −38.30
OA −40.00 −40.10 −42.00 −41.10 −40.90 −41.00 −40.40 −40.40
OC −36.40 −35.70 −35.60 −35.70 −35.90 −35.80 −35.40 −35.40
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safe value of −30 mV. However, in some mixtures oversize
droplets were also detected and according to the USP rules
fat droplets over 5 μm must not exceed the proportion of
0.05%. Proportions of second peaks are small (Table 1), but
this range of globule-size is on the borderline and exact
number of fat particles over 5000 nm has not been esti-
mated in this experiment. Therefore, from security reasons
in these cases use of lipid-filter is reasonable.
It was found an interesting phenomenon. The ten-
dency for separation of large diameter droplets in the
two emulsion systems is different. In case of Kabiven
second peak of droplets appears in the bottom of the
container in contrast to OliClinomel where the second
peak appears in the samples taken from the surface layer.
Interestingly this phenomenon is independent of cal-
cium-content. From therapeutic point of view we can
state that emulsions where the bigger droplets are in the
upper layer are safer because infusions are usually
infused with a small residual volume and the potentially
dangerous big droplets remain in the infusion bag. The
difference between the two types of TPN mixtures could
be partly explained by the different glucose content and
its effect on the osmolarity and the slightly different
density of the two emulsions. The higher osmolarity
(1190 mOsm/l vs 1060 mOsm/l) and lower density
(1.039 g/ml vs 1.049 g/ml) of OliClinomel resulted in
droplets of higher particle sizes in the therapeutically
safer surface layer [16]. Further targeted studies can
elucidate this phenomenon. Maybe the difference in
composition of the oversize droplets could explain the
experienced deviation. Nevertheless it is unlikely that
droplet-size differences are results of olive oil or soybean
oil content.
Conclusion
Zeta-potential of the droplets in experimental emul-
sions proved the stability of the colloid system, but size-
distribution showed disparity within the test mixtures. In
two of the four mixtures bimodal droplet-size distribu-
tion figures were detected and appearance of fat particles
over 5 μm can not be disclosed. The bimodality wasindependent of the Ca2+ content. Until the destabilizing
component is not identified and the consequent different
aggregation behavior of the two types of TPN is not
clarified, the lipid filter usage is advised in the course
of the parenteral nutrition.
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